# Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

> **NCT02953652** · PHASE2 · COMPLETED · sponsor: **HUYABIO International, LLC.** · enrollment: 55 (actual)

## Conditions studied

- Peripheral T-Cell Lymphoma (PTCL)

## Interventions

- **DRUG:** HBI-8000

## Key facts

- **NCT ID:** NCT02953652
- **Lead sponsor:** HUYABIO International, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2022-02-17
- **Final completion:** 2022-02-17
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02953652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02953652, "Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02953652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*